Slide 1: Q1 2026 results
Q1 2026 results Strong execution and pipeline momentum Conference call and webcast for analysts and investors 28 April 2026
Slide 2: Forward-looking statements
Forward-looking statements In order to utilise the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum AB (publ) is providing the following cautionary statement. This presentation contains forward-looking statements with respect to
Slide 3: Agenda
Agenda Business Update - Guido Oelkers Chief Executive Officer R&D Pipeline - Lydia Abad-Franch Head of R&D and Medical Affairs, Chief Medical Officer Financials - Henrik Stenqvist Chief Financial Officer Summary and Q&A
Slide 4: Key takeaways for Q1 2026
Key takeaways for Q1 2026 Strong Q1 performance: +24% growth at CER and 38% adjusted EBITA margin Six major launches and priority pipeline projects on track Aspaveli C3G / IC-MPGN launched with strong initial patient uptake Tryngolza sHTG EMA filing submitted and FCS launch progressing across Europe
Slide 5: Strong growth of 24% at CER in Q1 delivered by our portfolio and across all regions
Strong growth of 24% at CER in Q1 delivered by our portfolio and across all regions Total net sales, SEK M, growth at CER Strategic portfolio, SEK M Revenue by region Doptelet 1 433 +44% Strategic1 +24% Foundational Europe 2,866 +20% 7,184 Altuvoct 1 240 +186% 6,465 Gamifant 734 +47% Aspaveli / Nort
Slide 6: Strong launch cadence and milestone achievement continues building a highly differentiated portfolio
Strong launch cadence and milestone achievement continues building a highly differentiated portfolio Timeline Status Q1/26 2024 2025 2026 2027 2028 2029 2030 Haemophilia A Strong launch momentum Filing HLH/MAS in EU & HLH/MAS Japan Europe launch in Germany C3G & IC-MPGN and Austria Uncontrolle
Slide 7: Altuvoct: Rapid expansion of our share in Haemophilia A prophylaxis in our territory
Altuvoct: Rapid expansion of our share in Haemophilia A prophylaxis in our territory Haemophilia A sales SEK 2,026 M +25% Q1 Altuvoct: Best in class product • Continued strong momentum of Altuvoct (+186% growth at CER) • Launched in 27 countries with major markets in Europe now launched Altuvoct lau
Slide 8: Gamifant: US launch in HLH/MAS driving growth with strong momentum
Gamifant: US launch in HLH/MAS driving growth with strong momentum Gamifant SEK 734 M +47% Q1 HLH/MAS launch • First-ever treatment for adults and children with Macrophage Activation Syndrome (MAS) in Still's disease • Strong patient demand continues to drive growth • EU and Japan filing completed f
Slide 9: Aspaveli: Initial positive launch in Germany supported by best-in-class data for C3G and IC-MPGN
Aspaveli: Initial positive launch in Germany supported by best-in-class data for C3G and IC-MPGN Aspaveli SEK 371 M +21% Q1 Strong early launch momentum • Q1 growth driven by C3G and IC-MPGN, with PNH remaining stable • Approved in both the EU and Canada for C3G and IC-MPGN • Nephrology launch under
Slide 10: Doptelet: Continues to deliver strong momentum globally
Doptelet: Continues to deliver strong momentum globally Doptelet SEK 1,433 M +44% Q1 Doptelet still accelerating as a high-growth global franchise • Doptelet’s differentiated profile – strong efficacy with fewer dietary restrictions – combined with excellent execution has established it as a leading
Slide 11: Arthrosi Therapeutics: Establishing Sobi as a leader in gout
Arthrosi Therapeutics: Establishing Sobi as a leader in gout Pozdeutinurad: A rationally engineered highly Building a leading Gout Franchise selective new treatment approach • Next generation URAT1 inhibitor, once daily oral Uncontrolled Launch NASP in 2026 • Robust preclinical & clinical package go
Slide 12: Q1 R&D Pipeline
Q1 R&D Pipeline Lydia Abad-Franch Head of R&D and Chief Medical Officer
Slide 13: Continued pipeline progress in Q1 2026
Continued pipeline progress in Q1 2026 C3G & primary IC-MPGN Aspaveli EU approval Interferon-gamma-driven sepsis (IDS) Gamifant Topline data presented at ISICEM and WSC Severe hypertriglyceridemia (sHTG) Tryngolza Submitted for sHTG in EU Myelofibrosis Vonjo PACIFICA Phase 3 confirmatory study fully
Slide 14: Emapalumab in IDS: Proof-of-concept data presented at ISICEM and World Sepsis Congress
Emapalumab in IDS: Proof-of-concept data presented at ISICEM and World Sepsis Congress Primary endpoint at 28 days: Secondary endpoint at 90 days: decrease of SOFA score at the end of treatment1 sustained survival benefit2 ISICEM, 18 March 2026 WSC, 22 April 2026 100 80 % +/- 95%CIs 60 <<<< 40 60.0%
Slide 15: Progress to be continued in 2026
Progress to be continued in 2026 Anticipated pipeline news flow 2026 H1 2026 H2 NASP – Uncontrolled gout Aspaveli – C3G & primary IC-MPGN o US regulatory decision o Japan regulatory decision Pozdeutinurad – Progressive gout Gamifant – HLH / MAS in Still’s disease o REDUCE-2 (AR882-302) data readout
Slide 16: Q1 Financials
Q1 Financials Henrik Stenqvist Chief Financial Officer
Slide 17: Q1 2026 Revenue and profit & loss
Q1 2026 Revenue and profit & loss Q1 Q1 Full-year Total revenue (SEK M) Amounts in SEK M 2026 2025 Change 2025 Haematology Immunology Specialty Care Total revenue 7,184 6,465 11% 28,238 Adjusted Gross profit1,2 5,500 4,968 11% 22,270 7,821 Adjusted Gross margin1,2 77% 77% 79% 7,776 347 341 7,184 EBI
Slide 18: Sobi Outlook 2026 - unchanged
Sobi Outlook 2026 - unchanged Key drivers for 2026 outlook 2026 Outlook • Progress with commercial portfolio and continued Altuvoct launch Revenue • Critical investments in 2026 for future revenue growth: Anticipated to grow by a low • SG&A investment in Aspaveli in nephrology double-digit percentag
Slide 19: Summary and Q&A
Summary and Q&A Guido Oelkers Chief Executive Officer
Slide 20: We continue to make progress towards our 2030 ambition of doubling Sobi to 55bn SEK
We continue to make progress towards our 2030 ambition of doubling Sobi to 55bn SEK1 Revenue, in SEK B ILLUSTRATIVE ONLY, NOT TO SCALE 6 major launches 55 Altuvoct in HA Gamifant HLH/MAS Priority Portfolio development renewal programs through NASP in uncontrolled BD gout Gamifant in IDS Strategic gr
Slide 21: Q&A
Q&A
Slide 22: Current Development Pipeline
Current Development Pipeline Major ongoing clinical studies and medicines in registration in a major region or country Phase 2 Phase 3 Registration Vonjo® (pacritinib) Vonjo® (pacritinib) Tryngolza® (olezarsen) VEXAS (Vacuoles, E1 enzyme, X-linked, Myelofibrosis with severe Severe Hypertriglyceridem
Slide 23: Q1 2026 sustainability performance
Q1 2026 sustainability performance Sobi sustainability priorities Highlights in Q1 2026 Highlights in Q1 2026 Maintain commitment to Always act responsibly patients • Access to treatment • Safe and healthy working • Awareness and patient support • Patient centricity and conditions • Caring for emplo
Slide 24: Thank you
Thank you Sobi is a trademark of Swedish Orphan Biovitrum AB (publ). © Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm • Sweden www.sobi.com